Disease · MONDO_0006713
Trials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
1 to 14 of 14
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00512876 | Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization | Not applicable | 24 | 2013-07-03 | Corneal Neovascularization | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00559936 | Topical Avastin for Treatment of Corneal Neovascularization | Phase 1 | 24 | 2012-09-24 | Corneal Neovascularization | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01257750 | Treatment of Corneal Neovascularization With Topical Pazopanib | Phase 1/2 | 20 | 2012-11-06 | Corneal Neovascularization | PAZOPANIB | Its record names the disease | ClinicalTrials.gov |
| NCT00681889 | Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV) | Phase 1 | 9 | 2012-11-08 | Corneal Neovascularization | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04787471 | Corneal Crosslinking for Treatment of Corneal Neovascularization | Phase 2/3 | 138 | Corneal Neovascularization | RIBOFLAVIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04215393 | An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization | Phase 1 | 39 | Corneal Neovascularization | CONBERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT01501760 | Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea | Phase 3 | 38 | Corneal Newvessels | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00555594 | Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization | Phase 2/3 | 18 | Corneal Neovascularization | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00681603 | Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization | Not applicable | 13 | Lipid Keratopathy, Penetrating Keratoplasty, Herpetic Keratopathy, Rosacea | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00992849 | Bevacizumab for the Treatment of Corneal Neovascularization | Phase 2 | 10 | Corneal Neovascularization | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02797704 | Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization | Phase 1/2 | 6 | Corneal Neovascularization | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT00769145 | Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery | Phase 1 | 5 | Corneal Neovascularization | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01868360 | Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea | Phase 1 | 2 | Corneal Neovascularization | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT00515684 | Corneal Thinning During Topical Bevacizumab Therapy | Not applicable | 0 | Corneal Neovascularization | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006713/trials